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Background: Prostate cancer is a commonly diagnosed and treated malignancy, although it rarely presents with
cutaneous metastases. In this case presentation, we describe the diagnosis and treatment with radiotherapy of a
patient who presented with cutaneous metastases on his chest wall secondary to prostate cancer.
Case presentation: In 2006, a 73-year-old Caucasian gentleman with metastatic castration resistant prostate cancer
treated with mitoxantrone and prednisolone presented with cutaneous nodules on his chest wall. A punch biopsy
diagnosed cutaneous metastases, with histological confirmation with positive staining for cytokeratin, PSA (prostate
specific antigen) and PAP (prostatic acid phosphatise). Systemic treatment was ceased due to progressive disease;
radiotherapy was used to treat these nodules with a durable clinical response. The patient died five months after
initial diagnosis of cutaneous metastases.
Conclusions: In this report, a rare metastatic manifestation of a common malignancy is presented. Whilst dermal
metastases carries a poor prognosis from reported literature, this is the first report of radiotherapy providing a
durable clinical response with relief from bleeding and pain.
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Prostate cancer is the most commonly diagnosed cancer
in Australia, with an estimated incidence of 18,560 in
2012 [1]. However, the skin is an uncommon site of me-
tastasis and constitutes 5.3% of metastatic sites for all
cancers [2]. In prostate cancer, cutaneous metastasis is
very rare with a published incidence of 0.36% [3] - when
it occurs, it usually presents as nodules in the inguinal
region and anterior thigh [4]. Cutaneous metastases can
also be inflammatory, fibrotic or sclerodermoid [5], and
symptomatically, can be on a spectrum of being asymp-
tomatic to being ulcerative and painful [6].
Metastasis to the chest wall is uncommon, although
there is one case report published of cutaneous metasta-
sis to the neck and upper chest [7]. The mechanism of
spread is not entirely understood – direct extension,
lymphatic and haematogenous spread or combination of
these, have all been proposed [3,6,8-10].* Correspondence: gwhmak@gmail.com
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resistant prostate cancer, who presented with cutaneous
nodules confirmed to be metastases from his prostate
cancer. This was subsequently treated by radiotherapy,
with a clinically durable response. It is of interest for the
rarity of its presentation, and potential treatment with
radiotherapy.
Case presentation
In 2006, a 73-year-old Caucasian man presented with
nodular lesions on the left chest wall while receiving
mitoxantrone and prednisolone for metastatic hormone
refractory prostate cancer with skeletal metastases. At
the time, mitoxantrone was the standard systemic che-
motherapy for this condition, this gentleman was first
diagnosed with prostate cancer 9 years previously. Past
treatments included androgen deprivation, strontium,
carboplatin–etoposide, radiotherapy to the chest wall for
pain in the manubrium and sternum; and also with cispla-
tinum–phenoxidiol (as part of a phase 1 clinical trial). He
initially responded well to mitoxantrone with a fall in the
serum prostate specific antigen (PSA) and resolution of
bone pain.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Dermal infiltrate – Haematoxylin and eosin (H & E) stain.
Figure 2 Dermal infiltrate - positive for prostate specific
antigen (PSA) stain.
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ported having skin lesions on his chest. The lesions were
non-tender, pink, raised and occurred in irregular clus-
ters just lateral to the nipple towards the mid axillary
line, there were no epidermal changes. A clinical suspi-
cion of cutaneous metastases was considered along with
the differential diagnoses of a drug eruption and other
dermatoses.
A punch biopsy was performed on a sample lesion.
The pathology showed metastatic adenocarcinoma in
the dermis that stained for cytokeratin, PSA and pros-
tatic acid phosphatase (PAP) consistent with prostate
cancer (Figures 1 and 2). He was also found to have a
lower leg deep vein thrombus and was commenced on
enoxaparin then warfarin.
Chemotherapy was ceased due to progressive disease,
thereafter, serum PSA levels continued to rise. The PSA
increase coincided with increasing extent, size and pain
in the nodules on the chest wall. The lesions close to a
previous sternal ulcer became friable and bled easily
(Figure 3). Two months from when the lesions were firstnoticed, palliative radiotherapy of 18 Gy in 3 fractions
using electrons was delivered to the left chest wall to
good clinical effect (Figure 4).
The PSA continued to rise, however, and further
symptoms developed including fatigue, leg swelling and
dyspnoea. A computed tomography (CT) scan revealed
bilateral pleural effusions, the larger effusion on the
left was drained. The cytology of the fluid revealed ade-
nocarcinoma cells staining with anti-cytokeratin anti-
body CAM 5.2, PSA and PAP consistent with metastatic
disease.
The treated cutaneous lesions did not cause further
problems but new lesions were found out of the field of
radiotherapy treatment (Figure 4). He continued to de-
cline and required a second pleurocentesis. At this time
there were also changes on CT consistent with pulmo-
nary lymphangitis, he subsequently died in hospital 2
weeks later.
Conclusions
In prostate cancer, dermal involvement generally pre-
sents late in the disease and is associated with poor
prognosis [3,6]. One review of literature estimates mean
survival time from diagnosis of cutaneous metastasis at
being 7 months [9]. In this case, the patient had meta-
static prostate cancer for 9.5 years in total and died 5
months from the initial diagnosis of the skin metastases.
These occurred at failure of biochemical response to
chemotherapy, and became more extensive and symp-
tomatic as the PSA increased.
The mechanism of spread is uncertain – in our case,
the finding of pleural effusions with cytology positive for
prostate cancer cells in this case raises the possibility of
a transmural infiltration of metastases in the chest wall.
Histologically, there are multiple reported morphological
Figure 4 Left lateral chest wall, 39 days post radiotherapy
treatment.
Figure 3 Left lateral chest wall, two months after first
presentation.
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positivity for PSA and PAP. However, expected morpho-
logy and staining may not be present in a poorly diffe-
rentiated specimen [8,11,12].
This patient also had a significant and durable local re-
sponse to radiotherapy. The symptoms of bleeding and
pain completely subsided after treatment with 18 Gy in
3 fractions; although this did not lower serum PSA or
stop systemic progression.
Treatment options for cutaneous metastases include
local excision, intralesional chemotherapy [9] or radio-
therapy. Our literature review revealed no published re-
ports specifically for radiotherapy treatment for cutaneous
metastases of prostate carcinoma. In this case, we report
that radiotherapy can be a safe and effective treatment
with a durable response in this rare metastatic presenta-
tion of a common tumour.Consent
Written informed consent was obtained from the pa-
tient, prior to his death, for publication of this casereport and accompanying images. Furthermore, written
informed consent from the patient’s next-of-kin was also
sought post mortem, and a copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
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